학술논문
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
Document Type
article
Author
Francesca Palandri; Giuseppe A. Palumbo; Massimiliano Bonifacio; Elena M. Elli; Mario Tiribelli; Giuseppe Auteri; Malgorzata M. Trawinska; Nicola Polverelli; Giulia Benevolo; Alessia Tieghi; Fabrizio Cavalca; Giovanni Caocci; Eloise Beggiato; Gianni Binotto; Francesco Cavazzini; Maurizio Miglino; Costanza Bosi; Monica Crugnola; Monica Bocchia; Bruno Martino; Novella Pugliese; Marta Venturi; Alessandro Isidori; Daniele Cattaneo; Mauro Krampera; Fabrizio Pane; Daniela Cilloni; Gianpietro Semenzato; Roberto M. Lemoli; Antonio Cuneo; Elisabetta Abruzzese; Filippo Branzanti; Nicola Vianelli; Michele Cavo; Florian Heidel; Alessandra Iurlo; Massimo Breccia
Source
Cancers, Vol 15, Iss 20, p 5027 (2023)
Subject
Language
English
ISSN
2072-6694
Abstract
Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to therapy failure. As the therapeutic possibilities of MF are expanding, it is critical to identify patients predisposed to early ruxolitinib monotherapy failure and worse outcomes. We investigated predictors of early ruxolitinib discontinuation and death on therapy in 889 patients included in the “RUX-MF” retrospective study. Overall, 172 patients were alive on ruxolitinib after ≥5 years (long-term ruxolitinib, LTR), 115 patients were alive but off ruxolitinib after ≥5 yrs (short-term RUX, STR), and 123 patients died while on ruxolitinib after p = 0.08). Overall survival (OS) was significantly longer in LTR pts (p = 0.002). In multivariate analysis, PLT < 100 × 109/L, Hb < 10 g/dL, primary MF, absence of spleen response at 3 months and ruxolitinib starting dose